Accelerate Diagnostics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.18
Dividend & YieldN/A$ (N/A)
Beta 1.24
Market capitalization 85.27M
Operating cash flow -51.12M
ESG Scores unknown

Company description

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Sector: Healthcare - Industry: Medical Devices

Financial Ratios
Quick Ratio9.83
Working Capital-1.17
Return On Equity2.22
Debt To Equity-3.08
Fixed Asset Ratio1.12
Fixed Interest Cover-4.6

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -1.65M 1.04M -901k 348k
Total Cashflows From Investing Activities -20.14M 52.81M 13.61M 8.3M
Net Borrowings 171.5M 5.21M 5.21M -360k
Total Cash From Financing Activities 125.77M 6.82M 11.63M 43.23M
Change To Operating Activities 2.47M -2.11M -3.04M 251k
Issuance Of Stock 4.33M 6.82M 6.42M 34.68M
Net Income -88.33M -84.31M -78.21M -77.7M
Change In Cash 37.75M -5.25M -25.23M 4.12M
Effect Of Exchange Rate -130k -86k -78k -90k
Total Cash From Operating Activities -67.76M -64.79M -50.39M -47.32M
Depreciation 2.56M 2.6M 3M 2.52M
Change To Account Receivables 86k -1.36M 1.59M -770k
Other Cashflows From Financing Activities -4.99M -1.24M -1.24M -1.24M
Change To Netincome 14.48M 13.03M 17.35M 16.91M
Capital Expenditures -998k -330k -1.36M -603k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 27.64M 25.34M 21.25M 21.94M
Income Before Tax -88.11M -84.42M -78.2M -77.66M
Net Income -88.33M -84.31M -78.21M -77.7M
Selling General Administrative 55.21M 51.89M 46.5M 49.24M
Gross Profit 2.48M 4.4M 4.46M -381k
Ebit -80.37M -72.83M -63.3M -71.56M
Operating Income -80.37M -72.83M -63.3M -71.56M
Interest Expense -10.11M -14.26M -15.55M -15.54M
Income Tax Expense 211k -111k 5k 45k
Total Revenue 5.67M 9.3M 11.16M 11.78M
Cost Of Revenue 3.19M 4.9M 6.71M 12.16M
Total Other Income ExpenseNet -7.75M -11.59M -14.9M -6.1M
Net Income From Continuing Ops -88.33M -84.31M -78.21M -77.7M
Net Income Applicable To Common Shares -88.33M -84.31M -78.21M -77.7M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 127.89M 141.8M 156.24M 118.12M
Total Stockholder Equity 57.38M -7.38M -62.81M -35.08M
Other Current Liabilities 217k 271k 376k 451k
Total Assets 185.26M 134.42M 93.42M 83.05M
Common Stock 54k 55k 58k 68k
Other Current Assets 576k 1.17M 1.78M 1.56M
Retained Earnings -330.35M -414.65M -492.97M -570.67M
Treasury Stock -45.22M -45.12M -44.98M -45.13M
Cash 66.26M 61.01M 35.78M 39.9M
Total Current Liabilities 7.76M 8.16M 6.97M 6.95M
Other Stockholder Equity -149k -58k 91k -60k
Property, Plant, and Equipment 7.3M 11.82M 9.32M 7.9M
Total Current Assets 177.64M 121.85M 81.99M 73.33M
Net Tangible Assets 57.38M -7.38M -62.81M -35.08M
Net Receivables 1.86M 3.22M 1.55M 2.32M
Accounts Payable 1.32M 2.35M 1.29M 1.98M


Insider Transactions

Here are the insider transactions of stock shares related to Accelerate Diagnostics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MERTZ LARRY MICHAELPurchase at price 1.60 per share.D2022-08-30Chief Technology Officer50k
REICHLING STEVENPurchase at price 1.39 per share.D2022-08-22Chief Financial Officer5k
MERTZ LARRY MICHAELPurchase at price 1.35 per share.D2022-08-22Chief Technology Officer51.75k
PHILLIPS JACKSale at price 0.91 per share.D2022-06-22Chief Executive Officer28.2k
PHILLIPS JACKD2022-06-22Chief Executive Officer62.16k
REICHLING STEVENSale at price 0.98 per share.D2022-04-28Chief Financial Officer29.91k
PHILLIPS JACKSale at price 0.98 per share.D2022-04-28Chief Executive Officer83.71k
REICHLING STEVEND2022-04-26Chief Financial Officer57.74k
PHILLIPS JACKD2022-04-26Chief Executive Officer168.4k
PRICE RONSale at price 0.96 per share.D2022-04-22Officer15.07k
PRICE ROND2022-04-21Officer40.76k
PHILLIPS JACKSale at price 3.26 per share.D2022-02-01Chief Executive Officer3.65k
PHILLIPS JACKD2022-02-01Chief Executive Officer10k
MASSARANY HANYPurchase at price 3.30 per share.I2022-01-31Director20k
SCHULER JACK WPurchase at price 3.94 per share.I2022-01-18Director and Beneficial Owner of more than 10% of a Class of Security41.91k
SCHULER JACK WPurchase at price 3.89 - 4.03 per share.I2022-01-14Director and Beneficial Owner of more than 10% of a Class of Security131.22k
SCHULER JACK WPurchase at price 4.34 per share.I2022-01-10Director and Beneficial Owner of more than 10% of a Class of Security45.23k
SCHULER JACK WPurchase at price 4.93 per share.I2022-01-04Director and Beneficial Owner of more than 10% of a Class of Security10k
SCHULER JACK WPurchase at price 4.95 per share.I2021-12-30Director and Beneficial Owner of more than 10% of a Class of Security997
SCHULER JACK WPurchase at price 4.83 - 4.87 per share.I2021-12-29Director and Beneficial Owner of more than 10% of a Class of Security57.06k
SCHULER JACK WPurchase at price 4.73 per share.I2021-12-20Director and Beneficial Owner of more than 10% of a Class of Security54.54k
SCHULER JACK WPurchase at price 4.98 per share.I2021-12-17Director and Beneficial Owner of more than 10% of a Class of Security74.13k
SCHULER JACK WPurchase at price 4.60 per share.I2021-12-16Director and Beneficial Owner of more than 10% of a Class of Security20k
SCHULER JACK WPurchase at price 4.38 per share.I2021-12-15Director and Beneficial Owner of more than 10% of a Class of Security17.05k
SCHULER JACK WPurchase at price 5.00 per share.I2021-11-29Director and Beneficial Owner of more than 10% of a Class of Security1M
SCHULER JACK WPurchase at price 5.06 per share.I2021-11-22Director and Beneficial Owner of more than 10% of a Class of Security48.99k
SCHULER JACK WPurchase at price 5.19 per share.I2021-11-19Director and Beneficial Owner of more than 10% of a Class of Security56.85k
SCHULER JACK WPurchase at price 5.20 per share.I2021-11-18Director and Beneficial Owner of more than 10% of a Class of Security116.44k
MILLER MARK CStock Award(Grant) at price 5.83 per share.I2021-09-30Director13.02k
PATIENCE JOHNStock Award(Grant) at price 5.83 per share.I2021-09-30Director and Beneficial Owner of more than 10% of a Class of Security21.7k
BROWN THOMAS DStock Award(Grant) at price 5.83 per share.D2021-09-30Director8.68k
STROBECK MATTHEWStock Award(Grant) at price 5.83 per share.I2021-09-30Director19.53k
PHILLIPS JACKStock Award(Grant) at price 5.83 per share.D2021-09-30Chief Executive Officer4.34k
SCHULER JACK WPurchase at price 5.31 per share.I2021-09-28Director and Beneficial Owner of more than 10% of a Class of Security59.98k
SCHULER JACK WPurchase at price 5.33 per share.I2021-09-27Director and Beneficial Owner of more than 10% of a Class of Security150k
MASSARANY HANYPurchase at price 5.30 per share.I2021-09-27Director10k
SCHULER JACK WPurchase at price 5.45 per share.I2021-09-24Director and Beneficial Owner of more than 10% of a Class of Security192.2k
SCHULER JACK WPurchase at price 5.50 per share.I2021-09-23Director and Beneficial Owner of more than 10% of a Class of Security27.35k
PHILLIPS JACKSale at price 7.94 per share.D2021-06-22Chief Executive Officer23.48k
PHILLIPS JACKD2021-06-22Chief Executive Officer62.16k
REICHLING STEVENSale at price 6.76 per share.D2021-05-13Chief Financial Officer8.3k
PRICE RONSale at price 6.76 per share.D2021-05-13Officer6.28k
PHILLIPS JACKSale at price 6.76 per share.D2021-05-13Chief Executive Officer25.06k
REICHLING STEVEND2021-05-12Chief Financial Officer27.39k
PRICE ROND2021-05-12Officer19.34k
PHILLIPS JACKD2021-05-12Chief Executive Officer79.89k
MILLER MARK CStock Award(Grant) at price 7.68 per share.I2021-04-09Director13.02k
PATIENCE JOHNStock Award(Grant) at price 7.68 per share.I2021-04-09Director and Beneficial Owner of more than 10% of a Class of Security21.7k
BROWN THOMAS DStock Award(Grant) at price 7.68 per share.D2021-04-09Director8.68k
STROBECK MATTHEWStock Award(Grant) at price 7.68 per share.I2021-04-09Director19.53k
PHILLIPS JACKStock Award(Grant) at price 7.68 per share.D2021-04-09Chief Executive Officer4.34k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Accelerate Diagnostics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Accelerate Diagnostics Inc

Here is the result of two systematic investment strategies applied to Accelerate Diagnostics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Accelerate Diagnostics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Accelerate Diagnostics Inc:

Accelerate Diagnostics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -58.98% on the backtest period.

Performance at glance

Performance

-58.98 %

Latent gain

-1032.23 $

Invested capital

1750.27 $

Annualized return

-14.39 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Accelerate Diagnostics Inc

This is the result of two momentum investment strategies applied to Accelerate Diagnostics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Accelerate Diagnostics Inc

The following chart shows all the entries opened by the momentum investment system on Accelerate Diagnostics Inc:

Accelerate Diagnostics Inc momentum entries
  • The first momentum investment strategy would give -48.64% of return on Accelerate Diagnostics Inc. That represents -2075.12$ of latent gain with 4266.38$ of employed capital.
  • The second momentum investment strategy would give -48.66% of return on Accelerate Diagnostics Inc. That represents -1836.31$ of latent gain with 3773.78$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-48.64 %

Latent gain

-2075.12 $

Invested capital

4266.38 $

Annualized return

-21.74 %
Performance at glance (2Q Momentum)

Performance

-48.66 %

Latent gain

-1836.31 $

Invested capital

3773.78 $

Annualized return

-13.44 %

Momentum equity curve on Accelerate Diagnostics Inc

The following chart shows the equity curve of the two momentum strategies applied to Accelerate Diagnostics Inc:

Accelerate Diagnostics Inc momentum equity

Note: the dividends potentially given by Accelerate Diagnostics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Accelerate Diagnostics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Accelerate Diagnostics Inc since the beginning:

Accelerate Diagnostics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Accelerate Diagnostics Inc

Buy the dip entry openings on Accelerate Diagnostics Inc

Accelerate Diagnostics Inc

The performance achieved by the robo-advisor on Accelerate Diagnostics Inc is -45.65%. That represents -571.8$ of latent gain with 1252.7$ of employed capital. The following chart shows Accelerate Diagnostics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Accelerate Diagnostics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-45.65 %

Latent gain

-571.8 $

Invested capital

1252.7 $

Annualized return

-21.74 %

Equity curve of the strategy applied to Accelerate Diagnostics Inc

The following chart shows the result of the investment strategy applied to Accelerate Diagnostics Inc:

Accelerate Diagnostics Inc

Note: the dividends potentially given by Accelerate Diagnostics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Accelerate Diagnostics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Accelerate Diagnostics Inc:

Accelerate Diagnostics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Accelerate Diagnostics Inc

In this section, I will compare the three previous investment strategies applied to Accelerate Diagnostics Inc.

Equity curve comparison on Accelerate Diagnostics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Accelerate Diagnostics Inc investment strategy comparison

Employed capital comparison on Accelerate Diagnostics Inc

Accelerate Diagnostics Inc investment comparison

Performance comparison on Accelerate Diagnostics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -58.98% -1032.23$ 1750.27$ -14.39%
Momentum 1 quarter -48.64% -2075.12$ 4266.38$ -12.6%
Momentum 2 quarters -48.66% -1836.31$ 3773.78$ -13.44%
Non-directional -45.65% -571.8$ 1252.7$ -21.74%
Annualized return comparison

Automatic investment

-14.39 %

Momentum 1Q

-13.44 %

Momentum 2Q

-13.44 %

Non-directional

-21.74 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Accelerate Diagnostics Inc:

Positive correlations

Most correlated stocks this year

  • Accelerate Diagnostics Inc

  • Most correlated stocks last 3 months

  • MIKO INTL
  • Weibo Corp
  • Accelerate Diagnostics Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Accelerate Diagnostics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Accelerate Diagnostics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Accelerate Diagnostics Inc
    Country United States
    City Tucson
    Address 3950 South Country Club Road
    Phone 520 365 3100
    Website acceleratediagnostics.com
    FullTime employees 220
    Industry Medical Devices
    Sector Healthcare
    Exchange XNAS
    Ticker AXDX
    Market www.nasdaq.com

    Accelerate Diagnostics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown